PSABRE
Research type
Research Study
Full title
Psoriatic Arthritis Pathobiology and its Relationship with Clinical Disease Activity
IRAS ID
136079
Contact name
Stephen Kelly
Contact email
Sponsor organisation
Joint Research Management Office
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Psoriatic arthritis (PsA) is an important chronic inflammatory condition associated with skin psoriasis. Psoriasis affects approximately 2-3% of adults, of which at least 10-20% have some form of joint involvement. PsA is associated with a decreased quality of life and results in significant disability compared to the general population. Treatments currently available do not always work, and any response is not always complete. At present the reasons for the variation in response are not known.
The main hypothesis in this study is that there are specific, measurable, molecular and cellular markers present within the joint tissue or skin that define specific disease subsets and predict disease course, severity and response to treatment.
This study will be an observational study of a cohort of psoriatic arthritis patients who have failed to achieve sufficient response to standard non-biologic therapy. As they start their next treatment, this study aims to investigate the evolution of these patients in terms of the clinical, molecular and cellular profiles within the joint lining, peripheral blood and skin.
The aim is to identify a biomarker or panel of biomarkers which may provide important predictive information in terms of disease evolution and facilitate a more tailored approach to therapeutic intervention.
REC name
London - Bromley Research Ethics Committee
REC reference
15/LO/0584
Date of REC Opinion
8 Jun 2015
REC opinion
Further Information Favourable Opinion